CogRx sees Lilly solanezumab results support for its unique mechanism for Alzheimer’s disease treatment click here By John Harbison|2017-02-22T10:36:51-08:00November 23, 2016|Tech Coast Angels Portfolio Companies in the Press|Comments Off on CogRx sees Lilly solanezumab results support for its unique mechanism for Alzheimer’s disease treatment Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkXingEmail About the Author: John Harbison Related Posts
